Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery
- 22 January 2008
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 12 (2) , 223-238
- https://doi.org/10.1517/14728222.12.2.223
Abstract
(2008). Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opinion on Therapeutic Targets: Vol. 12, No. 2, pp. 223-238. doi: 10.1517/14728222.12.2.223Keywords
This publication has 128 references indexed in Scilit:
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Evidence for functional redundancy of class IA PI3K isoforms in insulin signallingBiochemical Journal, 2007
- The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformationProceedings of the National Academy of Sciences, 2006
- Phosphoinositide 3-Kinase C2β Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent MechanismsMolecular Biology of the Cell, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Cancer genes and the pathways they controlNature Medicine, 2004
- The Hallmarks of CancerCell, 2000
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994